Capsulin OAD is under clinical development by Diabetology (Products) and currently in Phase III for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase III drugs for Type 1 Diabetes (Juvenile Diabetes) have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Capsulin OAD’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Capsulin OAD overview
Capsulin OAD (oral anti-diabetic) is under development for the treatment of type 1 diabetes. It is an oral encapsulated formulation of human insulin which acts by targeting insulin receptor. It is developed based on Axcess drug delivery technology.
It was also under development for the treatment of type 2 diabetes.
Diabetology (Products) overview
Diabetology (Products) (Diabetology), a subsidiary of Proxima Concepts Ltd, is a biopharmaceutical company that develops oral drugs for the treatment of diabetes. The company provides oral delivery system to administer bioactive compounds to transform the treatment outcomes for patients with diabetes. Its pipeline products include capsulin OAD, capsulin IR, oral GLP-1 analog and combulin. Diabetology offers axcess, a system that increases the absorption of peptides, proteins and other macromolecules. Its capsulin OAD is an oral anti-diabetic used in the treatment of type 2 diabetes mellitus and oral GLP-1 analog reduces glucose output from the liver and improves insulin sensitivity and the function of beta-cells. The company operates in the UK and Australia. Diabetology is headquartered in London, England, the UK.
For a complete picture of Capsulin OAD’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
